Literature DB >> 1330163

The role of complement, platelet-activating factor and leukotriene B4 in a reversed passive Arthus reaction.

A G Rossi1, K E Norman, D Donigi-Gale, T S Shoupe, R Edwards, T J Williams.   

Abstract

1. The mechanisms underlying oedema formation induced in a reversed passive Arthus (RPA) reaction and, for comparison, in response to zymosan in rabbit skin were investigated. 2. Oedema formation at skin sites was quantified by the accumulation of intravenously-injected 125I-labelled human serum albumin. 3. Recombinant soluble complement receptor type 1 (sCR1), administered locally in rabbit skin, suppressed oedema formation induced in the RPA reaction and by zymosan. 4. The platelet-activating factor (PAF) antagonists, WEB 2086 and PF10040 administered locally, inhibited oedema formation induced in the RPA reaction and by PAF but not by zymosan. 5. A locally administered leukotriene B4 (LTB4) antagonist, LY-255283, inhibited oedema formation induced by LTB4 but did not inhibit oedema responses to PAF, zymosan or the RPA reaction. 6. The results demonstrate a role for complement in oedema formation in both the RPA reaction and in response to zymosan. An important contribution by PAF is indicated in the RPA reaction but not in response to zymosan whereas no evidence was obtained to suggest a role for LTB4 in either inflammatory response.

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1330163      PMCID： PMC1907593          DOI： 10.1111/j.1476-5381.1992.tb14461.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN： 0007-1188            Impact factor:   8.739


  26 in total

Review 1.  Complement ligand-receptor interactions that mediate biological responses.

Authors:  D T Fearon; W W Wong
Journal:  Annu Rev Immunol       Date:  1983       Impact factor: 28.527

Review 2.  Leukotriene receptor antagonists as potential therapeutic agents.

Authors:  D W Snyder; J H Fleisch
Journal:  Annu Rev Pharmacol Toxicol       Date:  1989       Impact factor: 13.820

Review 3.  Regulation of complement.

Authors:  T E Mollnes; P J Lachmann
Journal:  Scand J Immunol       Date:  1988-02       Impact factor: 3.487

4.  Depletion of plasma complement in vivo by a protein of cobra venom: its effect on various immunologic reactions.

Authors:  C G Cochrane; H J Müller-Eberhard; B S Aikin
Journal:  J Immunol       Date:  1970-07       Impact factor: 5.422

5.  Control of vascular permeability by polymorphonuclear leukocytes in inflammation.

Authors:  C V Wedmore; T J Williams
Journal:  Nature       Date:  1981-02-19       Impact factor: 49.962

6.  Pharmacological actions of WEB 2086, a new specific antagonist of platelet activating factor.

Authors:  J Casals-Stenzel; G Muacevic; K H Weber
Journal:  J Pharmacol Exp Ther       Date:  1987-06       Impact factor: 4.030

7.  Receptor antagonist of platelet activating factor inhibits inflammatory injury induced by in situ formation of immune complexes in renal glomeruli and in the skin.

Authors:  G Camussi; I Pawlowski; R Saunders; J Brentjens; G Andres
Journal:  J Lab Clin Med       Date:  1987-08

8.  Studies on the mechanism of the Shwartzman-phenomenon; evidence for the participation of polymorphonuclear leucocytes in the phenomenon.

Authors:  C A STETSON; R A GOOD
Journal:  J Exp Med       Date:  1951-01       Impact factor: 14.307

9.  Complement receptor is an inhibitor of the complement cascade.

Authors:  K Iida; V Nussenzweig
Journal:  J Exp Med       Date:  1981-05-01       Impact factor: 14.307

10.  Mediation of increased vascular permeability after complement activation. Histamine-independent action of rabbit C5a.

Authors:  T J Williams; P J Jose
Journal:  J Exp Med       Date:  1981-01-01       Impact factor: 14.307
View more
  8 in total

1.  Contribution of B(2) receptors for bradykinin in arthus reaction-induced plasma extravasation in wild-type or B(2) transgenic knockout mice.

Authors:  R Samadfam; C Teixeira; G Bkaily; P Sirois; A de Brum-Fernandes; P D'Orleans-Juste
Journal:  Br J Pharmacol       Date:  2000-04       Impact factor: 8.739

2.  Role of platelet-activating factor (PAF) in platelet accumulation in rabbit skin: effect of the novel long-acting PAF antagonist, UK-74,505.

Authors:  F Pons; A G Rossi; K E Norman; T J Williams; S Nourshargh
Journal:  Br J Pharmacol       Date:  1993-05       Impact factor: 8.739

3.  Effect of soluble P55 tumour-necrosis factor binding fusion protein on the local Shwartzman and Arthus reactions.

Authors:  K E Norman; T J Williams; M Feldmann; A G Rossi
Journal:  Br J Pharmacol       Date:  1996-02       Impact factor: 8.739

4.  Effect of PF 10040 on PAF-induced airway responses in neonatally immunized rabbits.

Authors:  C M Herd; D Donigi-Gale; T S Shoupe; S A Kilfeather; S A Okiji; C P Page
Journal:  Br J Pharmacol       Date:  1994-01       Impact factor: 8.739

5.  Role of adhesion glycoproteins CD18 and intercellular adhesion molecule-1 in complement-mediated reactions of rabbit skin.

Authors:  K E Norman; L W Argenbright; T J Williams; A G Rossi
Journal:  Br J Pharmacol       Date:  1994-01       Impact factor: 8.739

6.  Platelet-activating factor: the effector of protein-rich plasma extravasation and nitric oxide synthase induction in rat immune complex peritonitis.

Authors:  A A Steil; M C Garcia Rodriguez; A Alonso; M S Crespo; L Bosca
Journal:  Br J Pharmacol       Date:  1995-02       Impact factor: 8.739

7.  Studies on the mechanisms involved in the inflammatory response in a reversed passive Arthus reaction in guinea-pig skin: contribution of neutrophils and endogenous mediators.

Authors:  M M Teixeira; S M Fairbairn; K E Norman; T J Williams; A G Rossi; P G Hellewell
Journal:  Br J Pharmacol       Date:  1994-12       Impact factor: 8.739

8.  Immunoglobulin G-mediated inflammatory responses develop normally in complement-deficient mice.

Authors:  D Sylvestre; R Clynes; M Ma; H Warren; M C Carroll; J V Ravetch
Journal:  J Exp Med       Date:  1996-12-01       Impact factor: 14.307
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.